The cells expressing the T674I point mutant of FIP1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRa) in hypereosinophilics syndrome (HES) are resistant to imatinib and some second-generation tyrosine kinase inhibitors (TKIs). There is a desperate need to develop therapy to combat this acquired drug resistance. DCC-2036 has been synthesized as a third-generation TKI to combat especially the Bcr-Abl T315I mutant in chronic myeloid leukemia. This study evaluated the effect of DCC-2036 on FIP1L1-PDGFRa-positive cells, including the wild type (WT) and the T674I mutant. The in vitro effects of DCC-2036 on the PDGFRa signal pathways, proliferation, cell cycling and apoptosis of FIP1L1-PDGFRa-positive cells were investigated, and a nude mouse xenograft model was employed to assess the in vivo antitumor activity. We found that DCC-2036 decreased the phosphorylated levels of PDGFRa and its downstream targets without apparent effects on total protein levels. DCC-2036 inhibited proliferation, and induced apoptosis with MEK-dependent up-regulation of the pro-apoptotic protein Bim in FIP1L1-PDGFRa-positive cells. DCC-2036 also exhibited in vivo antineoplastic activity against cells with T674I FIP1L1-PDGFRa. In summary, FIP1L1-PDGFRa-positive cells are sensitive to DCC-2036 regardless of their sensitivity to imatinib. DCC-2036 may be a potential compound to treat imatinib-resistant HES.
Introduction
Idiopathic hypereosinophilic syndrome (HES) refers to the pathological presence of more than 1.5610 9 /L of nonreactive eosinophils in peripheral blood lasting for more than 6 months with organ involvement [1] . According to WHO classification system, HES can be classified as molecularly characterized eosinophilic disorders, such as platelet-derived growth factor receptor (PDGFR)-rearranged myeloid neoplasm, eosinophilia associated with phenotypically abnormal and/or clonal T lymphocytes, and chronic eosinophilic leukemia (CEL) [2] . Several genetic abnormalities such as PDGFRa, PDGFRb or FGFR1 have been observed in PDGFR-rearranged myeloid neoplasm [3] , and the FIP1L1-PDGFRa fusion gene generated by the interstitial deletion on chromosome 4q12 has been reported to account for 5% to 15% [4] . The expression of FIP1L1-PDGFRa can promote activation of pro-survival signal pathways, such as extracellular signal-regulated kinases (Erk), signal transducers and activators of transcription (STAT), JNK and PI3K-Akt signaling in CD34+ hematopoietic progenitor cells [5, 6] .
FIP1L1-PDGFRa is sensitive to imatinib treatment and patients with HES can be successfully treated with imatinib (100 mg/day) [7] . However, the secondary mutation T674I FIP1L1-PDGFRa in its kinase domain has been found in imatinib-refractory HES or CEL. T674I FIP1L1-PDGFRa, analogous to T315I Bcr-Abl in CML, is also resistant to the second-generation TKIs, such as nilotinib [8] . Novel agents for imatinib-resistant HES are needed.
DCC-2036, a conformational control inhibitor of ABL1, showed remarkable efficacy in murine bone marrow transplantation model of Bcr-Abl T315I CML [9] and potently suppressed the T315I Bcr-Abl in primary patient cells in vitro and in vivo [10] . Besides, DCC-2036 exhibited high selective activity for FLT3, TIE2 and SRC-family kinases [10] . Given the significant effect of DCC-2036 on Bcr-Abl T315I CML, we herein evaluated the efficacy of DCC-2036 against the FIP1L1-PDGFRa-expressing cells, including EOL-1 cell line and BaF3 cell lines harboring the WT or T674I FIP1L1-PDGFRa, to examine DCC-2036 as a strategy to overcome the drug-resistance of HES.
Materials and Methods
Reagents DCC-2036 was purchased from Selleck (Houston, TX, USA), sorafenib and imatinib were from Alexis Biochemicals (Plymouth Meeting, PA). They were dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 20 mmol/L (mM) and stored in aliquots at220uC. Antibodies against PARP, Bcl-2, X-linked inhibitor of apoptosis protein (XIAP) and cytochrome c (clone 6H2.B4) were obtained from BD Biosciences Pharmingen (San Jose, CA, USA); antibodies against phospho-PDGFRa (Y1018), phospho-Erk1/2 (T202/Y204), Erk 1/2, phospho-Akt (S473), total Akt, Bax, caspase-3, phospho-Bim (S69) and the MEK inhibitor U0126 were purchased from Cell Signaling Technology (Beverly, MA); antibodies against phospho-STAT3 (Y705), total STAT3, total PDGFRa were products of Upstate Technology; antibodies against Mcl-1 (S19), apoptosis-inducing factor (AIF), and Bax were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies against Bim were obtained from Stressgen Bioreagents (Columbia, Canada); antibodies against Survivin were purchased from Novus Biotechnology (Littleton, CO, USA); cycloheximide (CHX) and antibodies against Actin, active-caspase3 were from Sigma-Aldrich (St. Louis, MO); the PI3K inhibitor LY294002 and MG132 was bought from Calbiochem (San Diego, CA); antirabbit immunoglobulin G horseradish peroxidase-conjugated and anti-mouse immunoglobulin G antibodies were obtained from Pierce Biotechnology (Los Angeles, CA, USA) [11, 12] ; the plasmid Bim-EL was from Origene (Rockville, MD, USA); His-ubiquitin (His-Ub) plasmid was obtained from Abcam (Cambridge, MA); Ni-nitrilotriacetic acid (NTA) agarose beads were purchased from Invitrogen (Carlsbad, CA).
Cell culture
EOL-1 cell line harboring the FIP1L1-PDGFRa fusion oncogene and BaF3 cells carrying WT or T674I FIP1L1-PDGFRa (BaF3-WT or BaF3-T674I) were described previously [13, 14] . EOL-1 cells and BaF3 cells were cultured in RPMI-1640 medium (Invitrogen, Guangzhou, China), added with 10% fetal calf serum (Carlsbad, CA). Cells were cultured at 37uC and in water vapor-saturated air with 5% CO 2 .
Cell viability assay
Viable cells were quantified by MTS assay (Cell Titer 96 Aqueous One Solution reagent; Promega, Madison, WI) as previously described [11, 12] . 100 mL BaF3 cells or EOL-1 cells were plated in triplicate in 96-well plates (2610 4 cells per well) and then cultured with various concentrations of DCC-2036 for 72 hours. Twenty mL MTS solution per well was added 4 hours before culture termination. The absorbance was read on a 96-well plate reader at wavelength 490 nm. The drug concentration resulting in 50% decrease in the number of live cells (IC 50 ) was determined.
Immunoblotting analysis
Cells were incubated with different concentrations of DCC-2036 for indicated durations, washed, and then harvested by preparing whole lysates in RIPA buffer (16PBS, 0.5% sodium deoxycholate, 1% NP-40, 0.1% sodium dodecyl sulfate) supplemented with freshly added 10 mM b-glycerophosphare, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium orthovanadate, and 16Roche complete Mini protease inhibitor cocktail) (Roche, Indianapolis, IN, USA) [12, 15] . As for AIF and cytochrome c release detection, the cytosolic fraction was prepared in digitonin extraction buffer [1 mM PIPES (pH 6.8), 300 mM sucrose, 0.015% (wt/vol) digitonin, 3 mM MgCl 2 , 5 mM EDTA, 100 mM NaCl, and 1 mM PMSF] [12, 15, 16] . The concentration of protein was measured in a modified Lowry method at 750 nm wavelength (protein assay, Bio-Rad Laboratories, Hercules, CA). Proteins were resolved by molecular size by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membranes by electroblotting. Proteins were probed with the corresponding antibodies described above and chemiluminescence was used to detect the change of protein level with standard immunoblotting procedures according to the Manufacturer's instruction [17] .
Apoptosis assay by flow cytometry
After DCC-2036 treatment, cells were collected, washed with 16 Binding buffer, and then stained for about 20 minutes with Annexin V-FITC (fluorescein isothiocyanate) for EOL-1 cells or Annexin V-PE (phycoerythrin) for BaF3 cells expressing WT or T674I FIP1L1-PDGFRa. Propidium iodide (PI) or 7-aminoactinomycin (7-AAD) was added before flow cytometric analysis depending on the fluorophore attached to Annexin V. Apoptosis was assessed with the FACS Calibur flow cytometer and CellQuest Pro software (Becton Dickinson) as previously described [11, 12] .
Cell-cycle analysis by flow cytometry
After drug treatment, cells were harvested, fixed in 75% alcohol, and stained with propidium iodide (PI; Sigma-Aldrich) for 1 hour in dark according to manufacturer's guildance. Cell-cycle distribution was analyzed with FACS Calibur flow cytometer with CellQuest Pro software as described [11, 12] .
Clonogenicity assay
BaF3-WT and BaF3-T674I cells (2610 5 /mL) were exposed to indicated concentrations of DCC-2036 (DMSO for control) for 36 hours, then cells were collected, washed with 16 PBS, then cultured in methylcellulose media (Cat#03231; Stem Cell Technology). Absent of drug administration, after 7 days incubation at 37uC, colonies with more than 50 cells were counted under an inverted phase-contrast microscope. The capability of colony formation was assessed.
siRNA transfection
The siRNA against human Bim and non-targeting siRNAs (Mock siRNA as control) were purchased from Dharmacon RNA technology (Blenheim, England). Bim siRNA or Mock siRNA was transfected into the EOL-1 cells; then cells were incubated with indicated concentrations of DCC-2036 for 24 hours. Cell death and related protein levels were detected. The Cell Line Nucleofector Kit T involved was from Amaxa technology (Guangzhou, China), and Program O-17 was chosen according to the manufacturer's instructions [18] .
In vivo ubiquitination assay
The in vivo ubiquitination assay was carried out as previously described [19, 20] . In brief, BaF3 cells expressing T674I FIP1L1-PDGFRa were transfected with the indicated plasmids for 24 hours and then treated with or without DCC-2036 at 400 nM for 8 hours. Then the cells were lysed by a denaturing buffer (6 M guanidine-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM imidazole), followed by nickel bead purification and immunoblot analysis. The ubiquitinated BimEL was quantified by densitometry using Image J.
Nude mouse xenograft model
Nude nu/nu BALB/c mice (Slaccas Company, Shanghai, China) were housed in barrier facilities at the animal center of Sun Yatsen University, Guangzhou, China. The mice were bred in a 12-hour light-dark cycle environment with food and water available ad libitum. 9610 6 of BaF3 cells harboring the T674I FIP1L1-PDGFRa resuspended in Matrigel (Becton-Dickson Biosciences Pharmingen, San Jose, CA) were inoculated subcutaneously on the flank of the mice, which were about 4,6 weeks old [21] . When tumors were palpable (,100 mm random into two groups. One group received vehicle as control (0.5% Carboxymethylcellulose/1% Tween-80), the other group received DCC-2036 (200 mg/kg, daily, oral gavage) dissolved in 0.5% Carboxymethylcellulose/1% Tween-80. The tumors were calculated with calipers every other day, and the tumor volumes were measured by the following formula: a 2 6b60.4, where a is the smallest diameter and b is the diameter perpendicular to a. Other indicators of general health, such as body weight, feeding behavior, and motor activity of each animal were also monitored. After administration of drug or vehicle for about two weeks, the mice were sacrificed, and the tumor xenografts were immediately dissected, weighted, stored and fixed.
Ethics Statement
This study was conducted based on the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal studies were approved by Institutional Animal Care and Use Committee of Sun Yat-sen University (Protocol Number: 2012-0403). Sodium pentobarbital anesthesia methods and other efforts were taken to minimize animal suffering.
Immunohistochemical staining
Tumor xenografts were fixed in formalin, then embedded in paraffin and sectioned, and maxVision Kit (Maixin Bio) was used to immunostain the xenograft sections (4 mm). After incubation with the primary antibody of rabbit anti-Ki67 [21] , each slide was applied with about 50 mL maxVision reagent, followed by 0.05% diaminobenzidine and 0.03% H 2 O 2 in 50 mmol/L Tris-HCL (pH 7.6) to develop the color; then the slides were counterstained with hematoxylin. A negative control for Ki67 was developed for each xenograft specimen by replacing rabbit anti-Ki67 with preimmune rabbit serum.
Statistical analysis
All experiments were carried out at least three times, and data are expressed in the form of mean 6 standard deviation (SD) unless otherwise stated. Statistical analysis was conducted with GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). Two-tailed Student's t test was employed to compare the data between two groups, while One-Way ANOVA with post hoc intergroup comparison by Tukey test was for comparing more than two groups. A p,0.05 was considered statistically significant.
Results

DCC-2036 decreases the levels of phosphorylatedPDGFRa and its downstream signaling
EOL-1 cell line, derived from a patient with FIP1L1-PDGFRapositive HES [14] and BaF3 cells expressing wild-type or T674I FIP1L1-PDGFRa were employed in the study. EOL-1 cells exhibited a higher sensitivity to DCC-2036. Exposure to 6 nM DCC-2036 for 24 hours completely abolished the phosphorylation of PDGFRa in EOL-1 cells. Because the FIP1L1-PDGFRa T674I mutant in HES mainly contributes to the imatinib-resistance [22, 23] , we explored whether DCC-2036 could inhibit PDGFRa in FIP1L1-PDGFRa-positive cells regardless of the mutational status. DCC-2036 effectively decreased the phosphorylatedPDGFRa in BaF3 cells expressing FIP1L1-PDGFRa T674I mutant in a concentration-and time-dependent manner while the total protein level of PDGFRa was not affected ( Figure 1A &  B) . Similar results were observed in BaF3 cells expressing WT FIP1L1-PDGFRa.
Next, we measured the phosphorylation of downstream signaling proteins of PDGFRa in the three cell lines. In concordance with our previous finding, the phosphorylated levels of downstream signaling molecules such as the STAT3, Erk1/2, and Akt were all decreased by DCC-2036, without apparent impact on total protein levels ( Figure 1A & B) . Therefore, DCC-2036 inhibited the activation of phosphorylated-PDGFRa and its downstream signaling molecules in FIP1L1-PDGFRa-positive cells despite of the mutational status of FIP1L1-PDGFRa.
Because tyrosine kinase inhibitor sorafenib was effective for imatinib-resistant FIP1L1-PDGFRa T674I mutation cells [23] , we also compared the inhibitory effect of DCC-2036 with sorafenib in the BaF3-T674I cells. We found that DCC-2036 decreased the phosphorylated-PDGFRa with lower concentrations than sorafenib, indicating that DCC-2036 might be more potent ( Figure 1C ). Figure S1A and S1B). Treatment of 6 nM DCC-2036 for 24 hours led to ,40% cell death of EOL-1 (Figure 4) , while the apoptosis of BaF3 cells expressing WT or T674I FIP1L1-PDGFRa after treatment with 400 nmol/L DCC-2036 for 36 hours reached ,40% and ,80%, respectively, suggesting that BaF3-T674I cells were more sensitive to DCC-2036 than imatinib (Figure 4) .
DCC-2036 inhibits the proliferation of EOL-1 cells and BaF3 cells harboring wild-type or T674I FIP1L1-PDGFRa
Immunoblotting revealed that the cleavage of PARP and caspase-3, hallmarks of apoptosis, was increased in a concentration-and time-dependent manner, and were concurrent with the decline of PARP (116 kDa) and pro-caspase-3 (32 kDa) ( Figure 5A ). We observed no apparent change in other apoptosis-related proteins such as XIAP, Survivin, Bax, and Mcl-1, but there was an overt increase in Bim-EL protein level in a time-and dose-dependent manner ( Figure 5B and Figure S1C) .
Moreover, the release of AIF and cytochrome c from mitochondria into the cytosol, has been considered an indicator of cell apoptosis in the early phase [15, 24, 25] . Western blot exhibited a substantial release of AIF and cytochrome c into cytosol in both EOL-1 cells and BaF3 cells expressing WT or T674I FIP1L1-PDGFRa time-dependently ( Figure 5C ). These 
Elevated Bim-EL is essential for apoptosis induced by DCC-2036
It has been reported that Bim was critical for erlotinib-induced apoptosis in EGFR mutant lung cancer cells [26] and imatinibinduced apoptosis in KIT dependent GIST cells [27] . We investigated whether up-regulation of Bim ( Figure 5B ) was critical for DCC-2036-induced-apoptosis in HES cells. We transfected EOL-1 cells with Bim siRNA duplexes to silence the expression of Bim, or Mock siRNA as control, then EOL-1 cells were incubated with indicated concentrations of DCC-2036 for 24 hours. Apoptosis was evaluated by immunoblotting of PARP and by counting live cells with trypan blue dye exclusion. As shown in Figure 6A , knockdown of Bim remarkably attenuated apoptosis mediated by DCC-2036 in EOL cells, suggesting that Bim might be a critical mediator in DCC-2036-induced apoptosis in HES. Of note, Bim-extra long (EL) but not Bim-long (L) or Bim-short (S) is the primary isoform detected in these cells [28] , we thus turned our attention to Bim-EL isoform in subsequent experiments.
DCC-2036 mediates Bim-EL up-regulation by inhibiting its degradation
Given the critical role of Bim-EL, we further explored the potential mechanism that DCC-2036 induced Bim-EL upregulation. The mRNA level of Bim showed no significant change by qRT-PCR (data not shown), which suggested that DCC-2036 might increase Bim-EL at posttranscriptional levels. We examined whether the turnover rate of Bim-EL protein was affected by DCC-2036. BaF3 cells harboring WT or T674I FIP1L1-PDGFRa were treated with or without 400 nM DCC-2036 for 2 hours, then 100 mg/mL cycloheximide (CHX), a translation inihibitor, was added, and then cells were harvested at the indicated time point, immunoblotting showed that the turnover of Bim-EL was decelerated compared with cells absent of DCC-2036 treatment ( Figure 6B ), suggesting that DCC-2036 may increase Bim-EL protein level by reducing its turnover rate. Next, we investigated whether the proteasome pathway was involved in the degradation of Bim-EL protein. BaF3-T674I cells were pre-treated with 1 mM MG132 for 2 hours, then incubated with 400 nM DCC-2036 for 12 hours. Western blotting analysis revealed that the proteasome inhibitor MG132 led to increased expression of Bim-EL and there was no difference in the Bim-EL protein level between the MG132 treatment alone and combination of MG132 and DCC-2036 ( Figure 6C ), indicating that the upregulation of Bim-EL depended on the proteasome pathway.
It has been reported that Bim could be regulated by MEK-ERK or PI3K-Akt pathway [29, 30, 31] . Our data showed that both pathways were inhibited by DCC-2036, so we further explored which pathway was predominantly responsible for up-regulation of Bim-EL mediated by DCC-2036. EOL-1 cells were exposed to U0126 (a MEK inhibitor), LY294002 (a PI3K inhibitor), DCC-2036 or combination of them respectively. Western blot analysis revealed that DCC-2036 or U0126 alone induced up-regulation of Bim-EL. In contrast, EOL-1 cells treated with LY294002 did not exhibit any remarkable increase in Bim-EL protein level. Furthermore, combination of the two or three compounds didn't display additive effects on up-regulation of Bim-EL compared with U0126 treatment alone. All these data supported that DCC-2036 increased Bim-EL protein level predominantly through MEK-ERK pathway ( Figure 6D ). Erk1/2 can phosphorylate Bim-EL at serine69 (Ser69) eliciting a rapid polyubiquitination and proteosomal degradation [31] . In our study, we observed the protein level of phospho-Bim-EL (Ser69) declined significantly with DCC-2036 treatment of EOL-1 Figure 5B and Figure S1C ), which was consistent with declined phospho-Erk1/2 resulted from decreased phosphoPDGFRa by DCC-2036 ( Figure 1A and 1B) . Moreover, we found that polyubiquitinated Bim-EL decreased with treatment of DCC-2036 for 8 hours by ubiquitination assay in intact cells ( Figure 6E ), which suggested that the total Bim-EL in cells was increased.
DCC-2036 suppresses the growth of xenografted BaF3 cells harboring FIP1L1-PDGFRa T674I mutant in nude mice
To assess the in vivo effect of DCC-2036, we subcutaneously inoculated BaF3 cells expressing FIP1L1-PDGFRa T674I mutant in nude mice. When tumor xenografs were palpable (,100 mm 3 ), nude mice were randomized to receive vehicle (0.5% CMC/1% Tween 80, n = 6) or DCC-2036 (200 mg/kg in 0.5% CMC/1% Tween 80, once daily, oral gavage, n = 7) for about 2 weeks. The growth curve vs time of BaF3-T674I tumors was apparently inhibited by the administration of DCC-2036 compared with the control group ( Figure 7A ). In addition, the tumor volumes and tumor weights in the drug-treated group were remarkably lower than the control group ( Figure 7B ). The motor activity, feeding behavior and body weight of the control group and experiment group were all normal (data not shown).
Furthermore, Western blotting analysis of these BaF3-T674I xenograft tissues from mice exhibited downregulation of phosphorylated-PDGFRa and its downstream signaling molecules, them, respectively, for 24 hours, then cells were harvested and the indicated proteins were analyzed by immunoblotting. E, DCC-2036 decreases Bim-EL polyubiquitination. BaF3-T674I cells were transfected with Bim-EL along with His-ubiquitin (His-Ub). After 24 hours, the cells were treated with or without DCC-2036 at 400 nM for 8 hours, and then collected for in vivo ubiquitination of Bim-EL. The ubiquitinated BimEL was quantified by densitometry using Image J. The scale of ubiquitinated BimEL were normalized to that of relevant total BimEL, and then normalized to control. The ratio was shown. Ni-nitrilotriacetic acid (NTA), nickel bead precipitate; WCE, whole-cell extracts. doi:10.1371/journal.pone.0073059.g006 Figure 7D ). To conclude, all these data supported that DCC-2036 had a beneficial antineoplastic effect in vivo in spite of the T674I-FIP1L1-PDGFRa mutation status.
Discussion
Targeted therapy to inhibit the oncogene FIP1L1-PDGFRa has met with some success: the first-generation tyrosine kinase inhibitor (TKI) imatinib has been reported to be effective to HES, but imatinib-resistant mutations emerged. Several mutations in the kinase domains such as D842V [32] , T674I [33] , S601P and L629P [34] , have been demonstrated to be responsible for the drug-resistance. Of note, the ''gate-keeper'' mutant T674I FIP1L1-PDGFRa in HES, similar to T315I Bcr-Abl in CML, was also refractory to some second-generation TKIs, such as nilotinib, sorafenib [8] . Thus, it is really a challenge to overcome the acquired drug resistance. Combination therapy with more than one compound or other novel TKIs is advised. Imatinib combined with vinorelbine have been reported to enhance breast cancer cell growth inhibition via PDGFRb signaling [35] . Imatinib and farnesyltransferase inhibitors combination were used to treat Bcr-Abl-positive CML cells [36] . These examples inferred that combination therapy with compounds is feasible. Meantime, the third-generation TKIs (AP24534, HG-7-85-1, DCC-2036) have been developed [10, 37, 38] , but their efficacy and safety still need to be further validated in clinical trials. In this study, we mainly explored the effect of the novel TKI DCC-2036 on HES.
DCC-2036, a third-generation TKI, was rationally designed to specifically target the Bcr-Abl T315I mutant in CML by functioning as a conformational control inhibitor. The inhibition of kinase activity by DCC-2036 on unphosphorylated-Abl, phosphorylated-Abl, unphosphorylated-Abl T315I mutant and phosphorylated-Abl T315I mutant has been demonstrated (IC 50 values were 0.7560.11, 261, 561 and 461 nM, respectively) [10] . In addition, DCC-2036 also inhibited the Src family kinases (Src, Lyn, FGR and HCK) and the receptor TKs, such as KDR, FLT3 and TIE2 [10] . Notably, the inhibition of kinase activity by DCC-2036 on PDGFRa and PDGFRb was observed (IC 50 values were 70610 nM and 113610 nM, respectively) [10] . Based on the broad and notable effect of DCC-2036 on significant kinases, we evaluated the effect of DCC-2036 on WT or T674I FIP1L1-PDGFRa positive cells of HES in vitro and in vivo. Firstly, we found that DCC-2036 remarkably decreased the phosphorylation level of PDGFRa and its downstream signaling molecules such as phosphorylated-Erk1/2, phosphorylated-Akt and phosphorylated-STAT3 without any influence on the total level of these proteins. Secondly, DCC-2036 inhibited proliferation and induced apoptosis with the increased cleavage of PARP and caspase-3 in a concentration-and time-depended manner in HES cells. In addition, cytochrome c and AIF released from the mitochondrion into the endochylema were also increased. Data reflected that the intrinsic (mitochondrial) apoptotic pathway was involved. Flow cytometry also reflected increased apoptosis in a dose-and timedependent manner and increased sub-G1 apoptotic population. Thirdly, DCC-2036-mediated apoptosis of FIP1L1-PDGFRa positive cells depended on the up-regulation of Bim-EL, as other apoptosis-related proteins such as XIAP, Survivin, Bax, and Mcl-1 were not apparently influenced by DCC-2036 treatment, while Bim-EL protein level was obviously elevated. Moreover, knockdown of Bim by siRNA could attenuate the DCC-2036-mediated apoptosis in HES cells. Fourthly, DCC-2036 reduced the turnover rate of Bim-EL for decelerated degradation of Bim-EL, which depended on the ubiquitin-proteasome pathway after Bim-EL was phosphorylated at Ser69 by Erk1/2. Finally, our nude mouse model demonstrated that DCC-2036 had a good anti-tumor activity in vivo.
To conclude, our data demonstrate that DCC-2036 has potent activity against FIP1L1-PDGFRa positive HES cells regardless of the T674 mutation status in vivo and in vitro. Moreover, inhibitory effect of DCC-2036 was comparable to sorafenib in the FIP1L1-PDGFRa T674I mutation cells. In this study, we have also shown for the first time that Bim is essential for DCC-2036-mediated apoptosis in FIP1L1-PDGFRa positive cells. Taken together, DCC-2036 may be a promising agent for treating FIP1L1-PDGFRa-positive HES which is resistant to imatinib. 
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